Palonosetron
Palonosetron is a pharmaceutical drug with 56 clinical trials. Currently 1 active trials ongoing. Historical success rate of 97.8%.
Success Metrics
Based on 44 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
18
Mid Stage
25
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
95.7%
44 of 46 finished
4.3%
2 ended early
1
trials recruiting
56
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Cisplatin Disposition and Kidney Injury
Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis Patients
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
Clinical Trials (56)
Cisplatin Disposition and Kidney Injury
Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis Patients
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy
Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)
MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
PALONOSETRON X FOSAPREPITANT IN PONV
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients
Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery
Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 56